Vericel Corporation (NASDAQ: VCEL) Stock Competitors & Peer Comparison
See VCEL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VCEL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VCEL | $42.30 | -0.89% | 2.2B | 90.00 | $0.47 | N/A |
| VRTX | $547.59 | -0.08% | 139B | 28.78 | $19.03 | N/A |
| REGN | $828.50 | -0.66% | 85.4B | 18.16 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,011.11 | -2.76% | 62.9B | 91.26 | $11.08 | N/A |
| MRNA | $138.89 | -4.30% | 55.1B | -17.04 | -$8.15 | N/A |
| RVMDW | $12.03 | +1.95% | 47.7B | -1.69 | -$7.21 | N/A |
| RVMD | $211.58 | +1.01% | 45B | -23.99 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $371.98 | -0.66% | 39.7B | 65.49 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
VCEL vs VRTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, VRTX has a market cap of 139B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while VRTX trades at $547.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas VRTX's P/E ratio is 28.78. In terms of profitability, VCEL's ROE is +0.07%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, VCEL is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
VCEL vs REGN Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, REGN has a market cap of 85.4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while REGN trades at $828.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas REGN's P/E ratio is 18.16. In terms of profitability, VCEL's ROE is +0.07%, compared to REGN's ROE of +0.14%. Regarding short-term risk, VCEL is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
VCEL vs VRNA Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VCEL's ROE is +0.07%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, VCEL is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
VCEL vs ARGX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ARGX has a market cap of 62.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ARGX trades at $1,011.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ARGX's P/E ratio is 91.26. In terms of profitability, VCEL's ROE is +0.07%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, VCEL is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
VCEL vs MRNA Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, MRNA has a market cap of 55.1B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while MRNA trades at $138.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas MRNA's P/E ratio is -17.04. In terms of profitability, VCEL's ROE is +0.07%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, VCEL is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
VCEL vs RVMDW Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, RVMDW has a market cap of 47.7B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while RVMDW trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas RVMDW's P/E ratio is -1.69. In terms of profitability, VCEL's ROE is +0.07%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, VCEL is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
VCEL vs RVMD Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, RVMD has a market cap of 45B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while RVMD trades at $211.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas RVMD's P/E ratio is -23.99. In terms of profitability, VCEL's ROE is +0.07%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, VCEL is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
VCEL vs SGEN Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VCEL's ROE is +0.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VCEL is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
VCEL vs ONC Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ONC has a market cap of 39.7B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ONC trades at $371.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ONC's P/E ratio is 65.49. In terms of profitability, VCEL's ROE is +0.07%, compared to ONC's ROE of +0.14%. Regarding short-term risk, VCEL is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
VCEL vs ALNY Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ALNY has a market cap of 31.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ALNY trades at $236.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ALNY's P/E ratio is 42.52. In terms of profitability, VCEL's ROE is +0.07%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, VCEL is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
VCEL vs BNTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, BNTX has a market cap of 28.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while BNTX trades at $112.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas BNTX's P/E ratio is -14.63. In terms of profitability, VCEL's ROE is +0.07%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, VCEL is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
VCEL vs INSM Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, INSM has a market cap of 26.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while INSM trades at $123.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas INSM's P/E ratio is -30.17. In terms of profitability, VCEL's ROE is +0.07%, compared to INSM's ROE of -1.11%. Regarding short-term risk, VCEL is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
VCEL vs ROIV Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ROIV has a market cap of 26.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ROIV trades at $36.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ROIV's P/E ratio is -34.59. In terms of profitability, VCEL's ROE is +0.07%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, VCEL is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
VCEL vs INCY Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, INCY has a market cap of 25.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while INCY trades at $127.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas INCY's P/E ratio is 17.20. In terms of profitability, VCEL's ROE is +0.07%, compared to INCY's ROE of +0.30%. Regarding short-term risk, VCEL is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
VCEL vs UTHR Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, UTHR has a market cap of 21.8B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while UTHR trades at $512.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas UTHR's P/E ratio is 18.36. In terms of profitability, VCEL's ROE is +0.07%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, VCEL is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
VCEL vs GMAB Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, GMAB has a market cap of 20.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while GMAB trades at $33.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas GMAB's P/E ratio is 24.88. In terms of profitability, VCEL's ROE is +0.07%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, VCEL is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
VCEL vs BGNE Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VCEL's ROE is +0.07%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, VCEL is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
VCEL vs DNA-WT Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VCEL's ROE is +0.07%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, VCEL is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
VCEL vs JAZZ Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while JAZZ trades at $254.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas JAZZ's P/E ratio is 9.49. In terms of profitability, VCEL's ROE is +0.07%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, VCEL is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
VCEL vs BBIO Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, BBIO has a market cap of 15.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while BBIO trades at $81.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas BBIO's P/E ratio is -21.68. In terms of profitability, VCEL's ROE is +0.07%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, VCEL is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
VCEL vs ASND Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ASND has a market cap of 15.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ASND trades at $251.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ASND's P/E ratio is -104.11. In terms of profitability, VCEL's ROE is +0.07%, compared to ASND's ROE of +1.90%. Regarding short-term risk, VCEL is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
VCEL vs NBIX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while NBIX trades at $153.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas NBIX's P/E ratio is 22.12. In terms of profitability, VCEL's ROE is +0.07%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, VCEL is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
VCEL vs EXEL Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, EXEL has a market cap of 13.7B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while EXEL trades at $54.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas EXEL's P/E ratio is 15.59. In terms of profitability, VCEL's ROE is +0.07%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, VCEL is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check EXEL's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
VCEL vs HALO Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, HALO has a market cap of 12.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while HALO trades at $108.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas HALO's P/E ratio is 20.27. In terms of profitability, VCEL's ROE is +0.07%, compared to HALO's ROE of +1.81%. Regarding short-term risk, VCEL is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
VCEL vs KRTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VCEL's ROE is +0.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VCEL is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
VCEL vs BMRN Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, BMRN has a market cap of 12.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while BMRN trades at $65.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas BMRN's P/E ratio is 31.28. In terms of profitability, VCEL's ROE is +0.07%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, VCEL is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check BMRN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
VCEL vs ARWR Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ARWR has a market cap of 12.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ARWR trades at $86.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ARWR's P/E ratio is -38.55. In terms of profitability, VCEL's ROE is +0.07%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, VCEL is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
VCEL vs MDGL Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while MDGL trades at $511.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas MDGL's P/E ratio is -40.00. In terms of profitability, VCEL's ROE is +0.07%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, VCEL is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
VCEL vs TECH Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while TECH trades at $72.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas TECH's P/E ratio is 37.31. In terms of profitability, VCEL's ROE is +0.07%, compared to TECH's ROE of +0.09%. Regarding short-term risk, VCEL is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
VCEL vs RNAM Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VCEL's ROE is +0.07%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VCEL is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
VCEL vs AXSM Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while AXSM trades at $205.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas AXSM's P/E ratio is -53.63. In terms of profitability, VCEL's ROE is +0.07%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, VCEL is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check AXSM's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
VCEL vs IONS Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, IONS has a market cap of 10.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while IONS trades at $62.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas IONS's P/E ratio is -36.07. In terms of profitability, VCEL's ROE is +0.07%, compared to IONS's ROE of -1.11%. Regarding short-term risk, VCEL is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
VCEL vs PRAX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, PRAX has a market cap of 10.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while PRAX trades at $368.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas PRAX's P/E ratio is -28.46. In terms of profitability, VCEL's ROE is +0.07%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, VCEL is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check PRAX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
VCEL vs SMMT Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while SMMT trades at $12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas SMMT's P/E ratio is -11.37. In terms of profitability, VCEL's ROE is +0.07%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, VCEL is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
VCEL vs KRYS Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while KRYS trades at $341.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas KRYS's P/E ratio is 42.82. In terms of profitability, VCEL's ROE is +0.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VCEL is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check KRYS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
VCEL vs KYMR Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, KYMR has a market cap of 10B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while KYMR trades at $121.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas KYMR's P/E ratio is -37.83. In terms of profitability, VCEL's ROE is +0.07%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, VCEL is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check KYMR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
VCEL vs PTGX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while PTGX trades at $154.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas PTGX's P/E ratio is 150.21. In terms of profitability, VCEL's ROE is +0.07%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, VCEL is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check PTGX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
VCEL vs CYTK Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CYTK trades at $77.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CYTK's P/E ratio is -10.68. In terms of profitability, VCEL's ROE is +0.07%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, VCEL is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
VCEL vs RXDX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VCEL's ROE is +0.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VCEL is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
VCEL vs SYRE Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, SYRE has a market cap of 9.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while SYRE trades at $106.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas SYRE's P/E ratio is -54.69. In terms of profitability, VCEL's ROE is +0.07%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, VCEL is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check SYRE's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
VCEL vs NUVL Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas NUVL's P/E ratio is -21.79. In terms of profitability, VCEL's ROE is +0.07%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VCEL is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
VCEL vs CRNX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CRNX trades at $84.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CRNX's P/E ratio is -16.82. In terms of profitability, VCEL's ROE is +0.07%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VCEL is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CRNX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
VCEL vs IMVT Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, IMVT has a market cap of 8.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while IMVT trades at $43.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas IMVT's P/E ratio is -15.36. In terms of profitability, VCEL's ROE is +0.07%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, VCEL is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
VCEL vs PCVX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while PCVX trades at $61.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas PCVX's P/E ratio is -8.11. In terms of profitability, VCEL's ROE is +0.07%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, VCEL is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
VCEL vs IMGN Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VCEL's ROE is +0.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VCEL is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
VCEL vs TGTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while TGTX trades at $56.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas TGTX's P/E ratio is 20.29. In terms of profitability, VCEL's ROE is +0.07%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, VCEL is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check TGTX's competition here
Abivax S.A. (NASDAQ: ABVX)
VCEL vs ABVX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ABVX trades at $116.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ABVX's P/E ratio is -60.88. In terms of profitability, VCEL's ROE is +0.07%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, VCEL is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
VCEL vs BPMC Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VCEL's ROE is +0.07%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, VCEL is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
VCEL vs APGE Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while APGE trades at $134.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas APGE's P/E ratio is -31.13. In terms of profitability, VCEL's ROE is +0.07%, compared to APGE's ROE of -0.30%. Regarding short-term risk, VCEL is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
VCEL vs ALKS Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ALKS has a market cap of 8.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ALKS trades at $48.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ALKS's P/E ratio is 51.44. In terms of profitability, VCEL's ROE is +0.07%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, VCEL is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
VCEL vs CERE Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CERE's P/E ratio is -16.47. In terms of profitability, VCEL's ROE is +0.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VCEL is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
VCEL vs IBRX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while IBRX trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas IBRX's P/E ratio is -7.81. In terms of profitability, VCEL's ROE is +0.07%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, VCEL is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
VCEL vs RYTM Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, RYTM has a market cap of 7.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while RYTM trades at $111.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas RYTM's P/E ratio is -35.83. In terms of profitability, VCEL's ROE is +0.07%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, VCEL is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
VCEL vs MTSR Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VCEL's ROE is +0.07%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, VCEL is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
VCEL vs CAI Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CAI has a market cap of 7.4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CAI trades at $26.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CAI's P/E ratio is 73.42. In terms of profitability, VCEL's ROE is +0.07%, compared to CAI's ROE of +0.19%. Regarding short-term risk, VCEL is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check CAI's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
VCEL vs SRRK Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, SRRK has a market cap of 7B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while SRRK trades at $58.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas SRRK's P/E ratio is -16.87. In terms of profitability, VCEL's ROE is +0.07%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, VCEL is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check SRRK's competition here
CG Oncology Inc. (NASDAQ: CGON)
VCEL vs CGON Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CGON trades at $78.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CGON's P/E ratio is -29.08. In terms of profitability, VCEL's ROE is +0.07%, compared to CGON's ROE of -0.25%. Regarding short-term risk, VCEL is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
VCEL vs MRUS Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VCEL's ROE is +0.07%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, VCEL is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
VCEL vs ACLX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VCEL's ROE is +0.07%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VCEL is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
VCEL vs RETA Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas RETA's P/E ratio is -66.29. In terms of profitability, VCEL's ROE is +0.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VCEL is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
VCEL vs BLTE Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while BLTE trades at $158.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas BLTE's P/E ratio is -84.96. In terms of profitability, VCEL's ROE is +0.07%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, VCEL is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
VCEL vs CNTA Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CNTA's P/E ratio is -22.63. In terms of profitability, VCEL's ROE is +0.07%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VCEL is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CNTA's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
VCEL vs COGT Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, COGT has a market cap of 6.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while COGT trades at $36.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas COGT's P/E ratio is -17.17. In terms of profitability, VCEL's ROE is +0.07%, compared to COGT's ROE of -0.73%. Regarding short-term risk, VCEL is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check COGT's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
VCEL vs ORKA Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ORKA has a market cap of 6.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ORKA trades at $102.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ORKA's P/E ratio is -52.79. In terms of profitability, VCEL's ROE is +0.07%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, VCEL is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ORKA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
VCEL vs DNTH Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, DNTH has a market cap of 6.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while DNTH trades at $110.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas DNTH's P/E ratio is -26.52. In terms of profitability, VCEL's ROE is +0.07%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, VCEL is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check DNTH's competition here
Erasca, Inc. (NASDAQ: ERAS)
VCEL vs ERAS Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ERAS trades at $17.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ERAS's P/E ratio is -18.92. In terms of profitability, VCEL's ROE is +0.07%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, VCEL is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ERAS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
VCEL vs TVTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while TVTX trades at $65.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas TVTX's P/E ratio is -144.93. In terms of profitability, VCEL's ROE is +0.07%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, VCEL is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check TVTX's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
VCEL vs PTCT Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while PTCT trades at $71.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas PTCT's P/E ratio is -30.50. In terms of profitability, VCEL's ROE is +0.07%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, VCEL is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check PTCT's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
VCEL vs MIRM Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while MIRM trades at $96.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas MIRM's P/E ratio is -6.65. In terms of profitability, VCEL's ROE is +0.07%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, VCEL is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check MIRM's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
VCEL vs XENE Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, XENE has a market cap of 5.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while XENE trades at $60.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas XENE's P/E ratio is -12.89. In terms of profitability, VCEL's ROE is +0.07%, compared to XENE's ROE of -0.44%. Regarding short-term risk, VCEL is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check XENE's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
VCEL vs DFTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, DFTX has a market cap of 5.7B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while DFTX trades at $43.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas DFTX's P/E ratio is N/A. In terms of profitability, VCEL's ROE is +0.07%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, VCEL is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check DFTX's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
VCEL vs LGND Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, LGND has a market cap of 5.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while LGND trades at $280.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas LGND's P/E ratio is 30.76. In terms of profitability, VCEL's ROE is +0.07%, compared to LGND's ROE of +0.20%. Regarding short-term risk, VCEL is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
VCEL vs CDTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VCEL's ROE is +0.07%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, VCEL is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
VCEL vs ABCM Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VCEL's ROE is +0.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VCEL is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
VCEL vs ISEE Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VCEL's ROE is +0.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VCEL is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
VCEL vs CRSP Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CRSP trades at $57.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CRSP's P/E ratio is -11.99. In terms of profitability, VCEL's ROE is +0.07%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, VCEL is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check CRSP's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
VCEL vs APLS Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas APLS's P/E ratio is 38.35. In terms of profitability, VCEL's ROE is +0.07%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VCEL is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
VCEL vs ACAD Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ACAD has a market cap of 5.1B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ACAD trades at $29.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ACAD's P/E ratio is 13.36. In terms of profitability, VCEL's ROE is +0.07%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, VCEL is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
VCEL vs DYN Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while DYN trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas DYN's P/E ratio is -8.07. In terms of profitability, VCEL's ROE is +0.07%, compared to DYN's ROE of -0.64%. Regarding short-term risk, VCEL is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check DYN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
VCEL vs EWTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while EWTX trades at $44.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas EWTX's P/E ratio is -24.17. In terms of profitability, VCEL's ROE is +0.07%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, VCEL is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
VCEL vs TERN Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas TERN's P/E ratio is -51.41. In terms of profitability, VCEL's ROE is +0.07%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VCEL is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check TERN's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
VCEL vs FOLD Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VCEL's ROE is +0.07%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VCEL is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
VCEL vs AKRO Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VCEL's ROE is +0.07%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, VCEL is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check AKRO's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
VCEL vs PBLS Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, PBLS has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while PBLS trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas PBLS's P/E ratio is -43.67. In terms of profitability, VCEL's ROE is +0.07%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, VCEL is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check PBLS's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
VCEL vs ALPN Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VCEL's ROE is +0.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VCEL is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
VCEL vs CELC Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CELC trades at $90.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CELC's P/E ratio is -21.11. In terms of profitability, VCEL's ROE is +0.07%, compared to CELC's ROE of -3.51%. Regarding short-term risk, VCEL is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CELC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
VCEL vs ELVN Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ELVN has a market cap of 4.4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ELVN trades at $61.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ELVN's P/E ratio is -36.62. In terms of profitability, VCEL's ROE is +0.07%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, VCEL is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ELVN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
VCEL vs RLAY Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while RLAY trades at $19.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas RLAY's P/E ratio is -12.59. In terms of profitability, VCEL's ROE is +0.07%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, VCEL is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check RLAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
VCEL vs AMLX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, AMLX has a market cap of 4.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while AMLX trades at $38.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas AMLX's P/E ratio is -25.43. In terms of profitability, VCEL's ROE is +0.07%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, VCEL is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check AMLX's competition here
Opthea Limited (NASDAQ: OPT)
VCEL vs OPT Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas OPT's P/E ratio is -1.52. In terms of profitability, VCEL's ROE is +0.07%, compared to OPT's ROE of +1.18%. Regarding short-term risk, VCEL is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
VCEL vs PRTC Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas PRTC's P/E ratio is -3.78. In terms of profitability, VCEL's ROE is +0.07%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, VCEL is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
VCEL vs MRTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VCEL's ROE is +0.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VCEL is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check MRTX's competition here
Veradermics, Incorporated (NYSE: MANE)
VCEL vs MANE Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while MANE trades at $98.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas MANE's P/E ratio is -31.31. In terms of profitability, VCEL's ROE is +0.07%, compared to MANE's ROE of -0.29%. Regarding short-term risk, VCEL is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check MANE's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
VCEL vs ADPT Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while ADPT trades at $25.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas ADPT's P/E ratio is -62.32. In terms of profitability, VCEL's ROE is +0.07%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, VCEL is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ADPT's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
VCEL vs TNGX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while TNGX trades at $24.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas TNGX's P/E ratio is -29.53. In terms of profitability, VCEL's ROE is +0.07%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, VCEL is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check TNGX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
VCEL vs TLX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while TLX trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas TLX's P/E ratio is 121.92. In terms of profitability, VCEL's ROE is +0.07%, compared to TLX's ROE of +0.07%. Regarding short-term risk, VCEL is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check TLX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
VCEL vs VKTX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while VKTX trades at $33.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas VKTX's P/E ratio is -7.13. In terms of profitability, VCEL's ROE is +0.07%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, VCEL is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check VKTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
VCEL vs LEGN Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, LEGN has a market cap of 3.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while LEGN trades at $20.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas LEGN's P/E ratio is -30.79. In terms of profitability, VCEL's ROE is +0.07%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, VCEL is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check LEGN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
VCEL vs CPRX Comparison August 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2.2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, VCEL is priced at $42.30 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 90.00, whereas CPRX's P/E ratio is 12.30. In terms of profitability, VCEL's ROE is +0.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VCEL is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CPRX's competition here